No Data
Haisco Pharmaceutical Group (002653.SZ): Received the acceptance notification for the IND application of innovative drugs HSK44459 tablets.
On November 18, Gelonghui reported that haisco pharmaceutical group (002653.SZ) announced that it recently received the "Acceptance Notice" issued by the National Medical Products Administration, indicating that the clinical trial registration for the domestic production of HSK44459 tablets has been accepted. HSK44459 tablets are a new drug developed independently by the company with independent intellectual property rights for the treatment of Behçet's disease. According to the National Medical Products Administration's announcement on the release of the "Classification of Chemical Drug Registration and Application Materials Requirements" (Notice No. 44 of 2020), this product belongs to Class 1 chemical drugs. Preclinical research results indicate that this...
Haisco Pharmaceutical Group (002653.SZ) subsidiary obtained the IND acceptance letter for innovative drug HSK39004 inhalation powder aerosol.
Haisco Pharmaceutical Group (002653.SZ) released an announcement, the company's subsidiaries Tibet Haisco Pharmaceutical Co., Ltd. and Sichuan Haisco...
HiCisco: Q3 2024 Report
Haisco Pharmaceutical Group (002653.SZ) released its performance for the first three quarters, with a net income of 0.382 billion yuan, a year-on-year growth of 90.20%.
haisco pharmaceutical group (002653.SZ) released the third quarter report of 2024, achieving revenue of 2...
haisco pharmaceutical group (002653.SZ): net income of 0.382 billion yuan in the first three quarters, a year-on-year increase of 90.20%.
On October 29, Gelonhui reported that Haisco Pharmaceutical Group (002653.SZ) released its third quarter report for 2024, achieving revenue of 2.751 billion yuan in the first three quarters, a year-on-year increase of 15.41%; net income attributable to shareholders of the listed company was 0.382 billion yuan, a year-on-year increase of 90.20%; net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was 0.215 billion yuan, a year-on-year increase of 44.55%; with basic earnings per share of 0.3409 yuan.
Is Haisco Pharmaceutical Group (SZSE:002653) A Risky Investment?
What Haisco Pharmaceutical Group Co., Ltd.'s (SZSE:002653) 26% Share Price Gain Is Not Telling YouNo Data
No Data
